Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP - Trial NCT06054269
Access comprehensive clinical trial information for NCT06054269 through Pure Global AI's free database. This Phase 3 trial is sponsored by Centers for Disease Control and Prevention and is currently Recruitment Completed. The study focuses on Influenza. Target enrollment is 192 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centers for Disease Control and Prevention
Timeline & Enrollment
Phase 3
Nov 04, 2022
Nov 04, 2023
Primary Outcome
Hemagglutination inhibition (HI) geometric mean titers (GMT) pre- (Day 0) and post-vaccination (Day 28) of each vaccine reference virus,HI GMT pre- (Day 0) and post-vaccination (6 months),Geometric Mean Fold Rise (MFR) of each vaccine reference virus post-vaccination,MFR of each vaccine reference virus post-vaccination,Seroconversion rate (SCR) of each vaccine reference virus post-vaccination,SCR of each vaccine reference virus post-vaccination
Summary
This randomized, double-blinded trial will assess humoral immune responses to adjuvanted,
 egg-based quadrivalent influenza vaccines compared to standard dose, egg-based quadrivalent
 influenza vaccines among healthcare personnel (HCP). The trial will be conducted at two sites
 in Lima, Peru during 2022 and 2023.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06054269
Non-Device Trial